Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally” Rob de Ree
Voor meer informatie:
+31 (0) 35 760 65 05